HUTCHMED Announces European and Japanese Regulatory Acceptance for Orpathys Combined with Tagrisso in MET-Driven EGFR-Mutant Lung Cancer

Stock News11-02

HUTCHMED (00013) has announced that regulatory registration applications for the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) have been accepted in Europe and Japan.

In Europe, the European Medicines Agency (EMA) has validated and accepted a marketing authorization application submitted by AstraZeneca for the combination therapy to treat patients with locally advanced or metastatic non-small cell lung cancer with MET overexpression or amplification who have experienced disease progression during or after treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

In Japan, AstraZeneca has submitted a new drug application to the Japanese Ministry of Health, Labour and Welfare, which has been accepted, for the treatment of patients with unresectable advanced or recurrent non-small cell lung cancer who have experienced disease progression after EGFR-TKI treatment and who have MET overexpression or amplification.

Following the submission of a new drug application to the U.S. Food and Drug Administration (FDA) in September 2026 for the same indication, the acceptance of these regulatory registration applications in Europe and Japan marks further progress in advancing this innovative targeted combination therapy to benefit patients worldwide.

The positive results from the SAFFRON global Phase III study supported this new drug application. The results were presented at the Presidential Symposium session of the 2026 European Society for Medical Oncology (ESMO) Annual Meeting and simultaneously published in The New England Journal of Medicine.

The combination of Orpathys and Tagrisso demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with platinum-based doublet chemotherapy in patients whose disease had progressed after Tagrisso treatment. Compared with chemotherapy, the combination of Orpathys and Tagrisso reduced the risk of disease progression or death by 45% (based on PFS hazard ratio [HR] 0.55; 95% confidence interval [CI] 0.42-0.72; p<0.001).

In terms of median PFS assessed by blinded independent central review (BICR), the Orpathys plus Tagrisso group was 7.6 months, compared with 5.4 months in the control group. Results for the key secondary endpoint of OS showed that compared with chemotherapy, Orpathys plus Tagrisso reduced the risk of death by 32% (OS HR 0.68; 95% CI 0.50-0.91; p=0.010). Compared with the control group, Orpathys plus Tagrisso extended median OS by 4.9 months (17.8 months versus 12.9 months).

The safety profile of the combination therapy was consistent with the known safety profiles of each drug, and no new safety concerns were identified.

Third-generation EGFR-TKIs have significantly improved treatment outcomes for patients with EGFR-mutant non-small cell lung cancer. However, MET overexpression or amplification is one of the most common mechanisms of resistance following third-generation EGFR-TKI treatment. MET-driven resistance is often associated with poorer prognosis, and there remains a significant unmet clinical need for effective and well-tolerated treatment options in the later-line setting. Orpathys is co-developed by AstraZeneca and HUTCHMED and is commercialized by AstraZeneca.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment